TriArm Therapeutics Advances Non-Viral, Rapidly Manufactured FIT-CD19 CAR-T Therapy into U.S. Clinical Trials for Non-Hodgkin Lymphoma

Oct 23, 2023 11:23 CST Updated 11:23

TriArm Therapeutics

Cellular Immunotherapy Product Developer

▎WuXi AppTec Content Team Report

Recently, TriArm Therapeutics announced itsNon-Viral Rapid Preparation of FIT-CD19 CAR-T Immunotherapy for the Treatment of Non-Hodgkin's LymphomaHas received FDA approval for the IND application in the United States, officially entering the clinical trial phase.TriArm Therapeutics is a research and development company focused on non-viral preparation of CAR-T cell therapy solutions, while also developingA Variety of Innovative Cell Therapy Products。The company is committed to providing patients with efficient and cost-effective treatment solutions, bringing innovation and breakthroughs to the field of cancer immunotherapy.

CEO of TriArm TherapeuticsDr. Zhang Jie"This is a milestone in the development of TriArm, and also a great recognition of the relentless efforts of our team. This is an important step towards the wider and more effective application of CAR-T therapy. I would like to express my special thanks to every team member who has worked hard for this, to our investors, and to our peers in the industry."The uniqueness of this innovative therapy lies in the adoption of non-viral preparation technology, which shortens the preparation time to just two days, while the cost is only a fraction of currently available products.. The successful application of this breakthrough technology has not only improved production efficiency and reduced treatment costs, but also provided a more convenient and economical treatment option for a wider range of patients."

Chief Scientist of TriArm TherapeuticsDr. Jinhua Lu"We are very proud of the approval of FIT-CD19 CAR-T, and this success is inseparable from the close collaboration of the teams in both locations. This non-viral preparation technology platform, which we are proud of, can be quickly expanded to many cell therapy applications, making CAR-T cell therapy faster, more economical, and expected to bring benefits to more patients."

Public information shows that most of the currently marketed CAR-T cell products internationally are autologous cells genetically modified using viral vectors to combat hematological tumors. These cell therapies, on one hand, require a preparation process that takes about 1-2 months, and on the other hand, are relatively costly. FIT-CD19 CAR-T'sSpeed of preparationAndThe low cost of preparation, making this treatment plan有望普及到更多的医疗需求领域.

References:
[1]Nanjie Enterprise News | TriArm Therapeutics, Starchase Biotech (Shanghai) Non-Viral Rapid Preparation FIT-CD19 CAR-T Receives FDA Approval for Clinical Trials. Retrieved Oct 20, 2023, From https://mp.weixin.qq.com/s/vGzMEuVEbjoMWIp2iYg4Pg

This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media feeds. For authorization to repost, please leave a message on the "Pharma Observer" WeChat Official Account to contact us. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.